Vertex Kidney Drug Faces Infection-Risk Scrutiny — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vertex’s kidney disease drug was scrutinized for infection risk ahead of an FDA approval decision.
- American Society of Nephrology held its annual meeting in Denver, attended by kidney disease specialists and the investors and analysts who tag along.
Why it matters: For Vertex, the immediate material issue is regulatory: an FDA approval decision is approaching while infection risk is being scrutinized, putting safety into the decision’s context. The American Society of Nephrology meeting in Denver also shows the interested audience spans specialists plus investors and analysts.
Ask SkimNews
